New York Life Investment Management LLC Has $1.43 Million Position in DaVita Inc. (NYSE:DVA)

New York Life Investment Management LLC increased its stake in DaVita Inc. (NYSE:DVA) by 2.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 13,629 shares of the company’s stock after purchasing an additional 339 shares during the quarter. New York Life Investment Management LLC’s holdings in DaVita were worth $1,428,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DVA. IFM Investors Pty Ltd lifted its holdings in DaVita by 78.1% in the 3rd quarter. IFM Investors Pty Ltd now owns 21,115 shares of the company’s stock worth $1,996,000 after purchasing an additional 9,261 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in DaVita by 19.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,369 shares of the company’s stock worth $1,642,000 after purchasing an additional 2,790 shares during the last quarter. Park Avenue Securities LLC acquired a new stake in DaVita in the 3rd quarter worth approximately $332,000. CENTRAL TRUST Co lifted its holdings in DaVita by 93.3% in the 3rd quarter. CENTRAL TRUST Co now owns 1,448 shares of the company’s stock worth $137,000 after purchasing an additional 699 shares during the last quarter. Finally, TIAA Trust National Association bought a new position in DaVita in the 3rd quarter worth approximately $478,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Performance

DVA opened at $137.79 on Wednesday. The stock has a market cap of $12.08 billion, a PE ratio of 15.66, a P/E/G ratio of 1.17 and a beta of 1.04. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $145.04. The stock’s 50 day simple moving average is $134.15 and its 200-day simple moving average is $113.89.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The firm had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. During the same period in the prior year, the business posted $1.58 earnings per share. The business’s revenue was up 6.9% compared to the same quarter last year. Sell-side analysts forecast that DaVita Inc. will post 9.49 EPS for the current year.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares in the company, valued at approximately $61,629,578.67. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on DVA shares. UBS Group lifted their price target on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Truist Financial lifted their price target on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Monday. Finally, Barclays boosted their price objective on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, DaVita presently has an average rating of “Moderate Buy” and a consensus target price of $121.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.